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Abstract: Early identification of type 2 diabetes mellitus (T2DM) and hypertension (HTN) risk may
improve prevention and promote public health. Implementation of self-reported scores for risk
assessment provides an alternative cost-effective tool. The study aimed to develop and validate two
easy-to-apply screening tools identifying high-risk individuals for insulin resistance (IR) and HTN
in a European cohort. Sociodemographic, lifestyle, anthropometric and clinical data obtained from
1581 and 1350 adults (baseline data from the Feel4Diabetes-study) were used for the European IR
and the European HTN risk assessment index respectively. Body mass index, waist circumference,
sex, age, breakfast consumption, alcohol, legumes and sugary drinks intake, physical activity
and sedentary behavior were significantly correlated with Homeostatic Model Assessment of IR
(HOMA-IR) and/or HTN and incorporated in the two models. For the IR index, the Area Under
the Curve (AUC), sensitivity and specificity for identifying individuals above the 75th and 95th of
HOMA-IR percentiles were 0.768 (95%CI: 0.721–0.815), 0.720 and 0.691 and 0.828 (95%CI: 0.766–0.890),
0.696 and 0.778 respectively. For the HTN index, the AUC, sensitivity and specificity were 0.778
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(95%CI: 0.680–0.876), 0.667 and 0.797. The developed risk assessment tools are easy-to-apply, valid,
and low-cost, identifying European adults at high risk for developing T2DM or having HTN.
Keywords: European IR Risk Index; European HTN Risk Index; screening; type 2 diabetes; hypertension
1. Introduction
Despite the vast scientific research and the numerous health initiatives indicating that Type
2 Diabetes Mellitus (T2DM) is preventable, its prevalence is constantly rising. At the moment,
483 million people suffer from diabetes around the world. Although Europe holds the second lowest
prevalence of 6.3%, it is expected to increase to 7.3% and 7.8% by 2030 and 2045, respectively [1].
Similarly, hypertension (HTN), which is the strongest risk factor for all-cause mortality globally [2],
keeps on rising and affects one in four adults [3].
The importance of early identification of both T2DM and HTN has been well-documented [4–7].
The diagnosis of T2DM includes the assessment of fasting plasma glucose (FPG), 2-h plasma
glucose during an oral glucose tolerance test, or glycated hemoglobin (HbA1c) measurement [8].
Furthermore, according to the European Society of HTN, measurement of blood pressure in various
conditions, such as at the office or at home, or daytime versus night-time, determines its classification
from optimal blood pressure (BP) to grade 3 HTN [9]. However, since people with HTN have no
symptoms, they do not monitor their BP. Consequently, as shown in a recent review, 5–10% of subjects
with stage 2 HTN are undiagnosed or untreated [10]. Either because of the cost of blood tests, the
practical arrangements of being measured or the lack of symptoms, both for insulin resistance (IR)
and high BP, many people do not perform regular checks and, consequently, diagnosis is only made
often after severe complications have developed over time [11]. Therefore, the application of low-cost
and easy-to-apply methods for the early diagnosis of pre-diabetes and HTN could be a useful tool for
public health [12].
There is a growing number of screening tools assessing glycaemic and BP status via the
incorporation of various risk factors such as age, history of disease, sex, ethnicity, body mass
index (BMI), medication, etc. [13–17]. Regarding the manifestation of T2DM, there are many risk
scores and indices in the literature. However, most of them incorporate measures of blood glucose,
which is not always feasible to be measured, especially in populations of low socioeconomic status.
Additionally, none of them has been developed based on a multiethnic population. Moreover, most of
them do not take into account dietary habits as predictors [13,15,18,19]. Nonetheless, there is no risk
score identifying IR. Impaired insulin sensitivity represents early abnormalities in glycaemic control
and constitutes a great predictive index for T2DM [20,21]. In addition, the impact of IR on the capacity
metabolic roles of liver, adipose tissue and skeletal muscle is detrimental for human health [22]. As for
HTN, there are some prediction models developed, but their application does not suit to all ethnicities
and races [23], age groups [14], or incorporate, as well, BP measurements [16]. This is impractical
for many people as they do not regularly measure their BP, or it is misleading, as the reported BP
measurement does not represent an accurate estimation due to lack of proper assessment according to
the guidelines (i.e., standard conditions and measurements during three different visits) [24].
The aim of the current study was to develop and validate two risk assessment indices for the
identification of adults with IR (European IR Risk Index) and grade 2 and 3 HTN (European HTN Risk
index) via demographic, anthropometric, dietary and lifestyle parameters in a large European cohort.
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2. Materials and Methods
2.1. Study Background
The current study was based on the baseline data retrieved from the EU-funded
Feel4Diabetes-study, which intended to design, apply and evaluate an intervention program in schools
and communities in order to prevent T2DM among families across Europe. The Feel4Diabetes-study
was registered at clinicaltrials.gov as NCT02393872.
2.2. Ethics Approval and Consent to Participate
The Feel4Diabetes-study adhered to the Declaration of Helsinki and the conventions of the Council
of Europe on human rights and biomedicine [25]. All participating countries obtained ethical clearance
from the relevant ethical committees and local authorities. More specifically, in Belgium the study
was approved by the Medical Ethics Committee of the Ghent University Hospital (ethical approval
code: B670201524437); in Bulgaria, by the Ethics Committee of the Medical University of Varna
(ethical approval code: 52/10-3-2016r) and the Municipalities of Sofia and Varna, as well as the Ministry
of Education and Science local representatives; in Finland, by the hospital district of Southwest Finland
ethical committee (ethical approval code: 174/1801/2015); in Greece, by the Bioethics Committee
of Harokopio University (ethical approval code: 46/3-4-2015) and the Greek Ministry of Education;
in Hungary, by the National Committee for Scientific Research in Medicine (ethical approval code:
20095/2016/EKU); and in Spain, by the Clinical Research Ethics Committee and the Department of
Consumers’ Health of the Government of Aragón (ethical approval code: CP03/2016). All participants
gave their written informed consent prior to their enrolment in the study.
2.3. Study Protocol and Recruitment
A detailed description of the methodology of the Feel4Diabetes-study has been previously
published [26]. Briefly, the recruitment of the population study was carried out via a multi-stage
sampling procedure in selected provinces of six European countries (Hungary, Bulgaria, Finland,
Belgium, Greece and Spain). In each country, primary schools located in the selected municipalities
were used as the entry-point to the community and parents having children attending the first
three grades were invited to complete the Finnish Diabetes Risk Score (FINDRISC) and a brief
questionnaire on lifestyle habits (self-reported data). If at least one parent fulfilled the country- specific
cut-off point for FINDRISC (for the majority of countries that was set as a FINDRISC score ≥ 9),
both parents (regardless their individual FINDRISC score) were invited to undergo a brief medical
check-up. This procedure led to a cohort with a wide distribution of FINDRISC values among the
participating parents, i.e., 25.9%, 37.3% and 36.8% of participants had a total FINDRISC score <9,
9–11 and ≥12 respectively.
Exclusion criteria for the development of the two risk assessment indices were: previous diabetes
diagnosis, not following the fasting protocol, current antihypertensive treatment and incomplete data.
Therefore, from the initial 3153 parents, 1572 were excluded from the Homeostatic Model Assessment
of IR (HOMA-IR) index and 1786 were excluded from the HTN index, and this resulted in 1581
(Bulgaria, n = 367; Finland, n = 218; Belgium, n = 214; Greece, n = 476; and Spain, n = 306) and 1350
(Hungary, n = 19; Bulgaria, n = 361; Finland, n = 278; Belgium, n = 173; and Greece, n = 519) subjects
for each model, respectively. Insulin data were not analyzed in Hungary, thus the data obtained from
this country was not included the IR risk index. Similarly, the data obtained from Spain was excluded
from the HTN risk index, as alcohol intake was not recorded in this cohort. Blood pressure and blood
indices (i.e., insulin and glucose) were measured by trained researchers using standardized procedures
and calibrated equipment in every country as described elsewhere [26]. All variables used in the two
developed tools were self-reported (including anthropometric measurements).
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2.4. Measures
Questionnaire data: All the relevant data, such as sociodemographics (i.e., sex, age, educational level,
marital status, etc.), behavioral indices regarding dietary habits, physical activity and sedentary
behaviors (i.e., portions of sugary drinks per week, number of meals and snacks during a day,
minutes of daily vigorous physical activity, time spent in front of computers and television, etc.) were
collected from participants [26].
Anthropometry: All study participants received paper measuring tapes and brief written
instructions on how to measure their height, weight and waist circumference. BMI and waist
circumference were classified based on the World Health Organization (WHO) criteria [27].
BP measurement: BP was measured on the right arm, in a sitting position using electronic
sphygmomanometers (OMRON M6 or OMRON M6 AC, Omron Healthcare, Kyoto, Japan) after five
minutes of rest, on three occasions, at one-minute intervals. Participants were classified according to the
European guidelines [28] in the following categories: optimal (systolic BP < 120 mmHg and/or diastolic
BP < 80 mmHg), normal (systolic BP 120–129 mmHg and/or diastolic BP 80–84 mmHg), high normal
(systolic BP 130–139 mmHg and/ or diastolic BP 85–89 mmHg), grade 1 HTN(systolic BP 140–159 mmHg
and/ or diastolic BP 90–99 mmHg), grade 2 HTN (systolic BP 160–179 mmHg and/or diastolic BP
100–109 mmHg), and grade 3 HTN (systolic BP ≥ 180 mmHg and/or diastolic BP ≥ 110 mmHg), with the
BP category to be defined by the highest level of BP, either systolic or diastolic.
Blood indices: Blood samples were drawn in the morning after overnight fasting (duration:
eight hours or longer). FPG and fasting insulin was analyzed in accredited laboratories, using similar
enzymatic assays in all study centers. HOMA-IR was calculated as indicated by Matthews et al. [29].
2.5. Statistical Analysis
Factors associated with HOMA-IR and HTN were identified by Pearson’s or Spearman’s correlation
and analyses of variance. For dietary behavior and physical activity factors, receiver operating
characteristic (ROC) analysis was performed and the optimal cut-offs were determined by the
point with the shortest distance to (0,1) in the ROC curve that maximizes the sensitivity (Se) and
specificity (Sp) of the test. The distance for each observed cut-off was calculated as the square root of
[(1 − Se)2 + (1 − Sp)2] [30]. For other variables, such as waist circumference and BMI the cut-off values
set by WHO were used. The population was randomly separated to 2/3 and 1/3 for the development
(n = 1076 IR cohort and n = 906 HTN cohort) and validation (n = 505 IR cohort and n = 444 HTN
cohort) of the indices respectively. For the development of the risk assessment indices, backward linear
regressions were performed, with dependent variables the percentiles of HOMA-IR and 5 categories of
HTN classification, respectively. The exclusion criteria of independent variables were set at p > 0.10.
The adjusted β-coefficients were multiplied and rounded to the nearest integer value as needed so as
to sum up to 40 points. In order to validate the indices, ROC analysis was performed to the validation
cohort. The scores with the best combination of Se and Sp (determined as described previously),
for 75th and 95th percentile for HOMA-IR, and for grade 2 and 3 HTN, respectively, were used as
cut-off scores for the interpretation of the results. The statistical analyses were performed using the
Statistical Package for Social Sciences (SPSS Inc., Chicago, IL, USA), version 21.0.
3. Results
The descriptive characteristics of the study population for the European IR Risk Index and the
European HTN Risk Index are presented in Table 1. Moreover, the sex distribution was 33.8% males
and 66.2% females and 31.9% males and 68.1% females, for European IR Risk Index and the European
HTN Risk Index, respectively. None of the aforementioned variables differed significantly between
development and validation cohorts.
Nutrients 2020, 12, 960 5 of 13
Table 1. Descriptive characteristics of the European IR Risk Index and European HTN Risk Index.
Development
Cohort
Mean ± SD
Validation
Cohort
Mean ± SD
p Value
European IR Risk Index
(n = 1581)
n = 1076 n = 505
Age (years) 40.7 ± 5.29 40.6 ± 5.15 0.666
BMI (kg/m2)
male 29.7 ± 3.97 29.2 ± 4.39 0.172
female 27.3 ± 5.69 27.3 ± 5.67 0.985
Waist circumference (cm)
male 102.7 ± 9.93 101.0 ± 11.64 0.068
female 88.7 ± 13.31 89.1 ± 12.95 0.619
HOMA-IR 2.0 ± 2.40 1.9 ± 1.39 0.340
SBP (mmHg) 116.8 ± 16.20 116.4 ± 15.47 0.673
DBP (mmHg) 77.7 ± 11.39 77.0 ± 10.37 0.242
European HTN Risk
Index (n = 1350)
n = 906 n = 444
Age (years) 40.1 ± 5.34 40.3 ± 5.47 0.590
BMI (kg/m2)
male 29.2 ± 3.58 29.1 ± 3.89 0.224
female 27.1 ± 5.04 27.2 ± 5.48 0.930
Waist circumference (cm)
male 102.8 ± 10.77 101.7 ± 12.07 0.330
female 87.6 ± 13.17 88.7 ± 13.41 0.268
HOMA-IR 2.2 ± 2.80 2.0 ± 1.46 0.145
SBP (mmHg) 117.5 ± 17.06 116.7 ± 16.51 0.466
DBP (mmHg) 77.9 ± 12.13 76.8 ± 11.06 0.092
BMI: Body Mass Index; HOMA-IR: Homeostatic Model Assessment of Insulin Resistance Index; SBP: Systolic blood
pressure; DBP: Diastolic blood pressure.
Regarding the European IR Risk index, the parameters found to be significantly associated with
the HOMA-IR were: number of breakfast occasions per week, unsweetened and sweetened milk
consumption, sugary drinks consumption, fish, red meat, fruits and vegetables consumption, BMI, sex,
waist circumference, number of walking sessions during the week lasting at least 30 min, number of
vigorous physical activity sessions during the week lasting at least 10 min and leisure screen time
(i.e., television, video games, computers, etc.). At the final model the variables found to be statistically
significant in identifying the HOMA-IR percentiles after the stepwise procedure were BMI, screen time,
sex, breakfast, sugary drinks, waist circumference, walking and vigorous physical activity as shown in
Table 2.
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Table 2. Scores for European IR Risk Index.
HOMA-IR Model b p Value Cut-Offs Points Allocated
BMI
0.001
- <25 kg/m2 0
0.340 25–30 kg/m2 9
0.680 >30 kg/m2 19
Waist Circumference (women and
men respectively)
0.003
- <80 cm or <94 cm 0
0.118 80–88 cm or 94–102 cm 3
0.236 >88 cm or >102 cm 7
Screen time
0.001
- <2 h/day 0
0.113 ≥2 h/day 3
Sex
0.023
- female 0
0.066 male 2
Breakfast
0.001
- ≥5 times/week 0
0.095 <5 times/week 3
Sugary drinks (1 portion = 250 mL)
0.018
- <1 portion/week 0
0.063 ≥1 portion/week 2
Walking
(3 days/ week for at least 30 min)
0.033
- Yes 0
0.057 No 2
Vigorous physical activity
(3 days/ week for at least 10 min)
0.002
- Yes 0
0.084 No 2
Maximum total points 40
b: standardizes-coefficient; BMI: Body Mass Index; HOMA-IR: Homeostatic Model Assessment of Insulin
Resistance Index.
As for the European HTN Risk Index the parameters found to be significantly associated with
the BP categories as determined by the ESH were: number of cigarettes per day, number of lunch
occasions per week, morning snacks per week, afternoon snacks per week, evening snacks per week,
whole grain foods consumption (i.e., whole wheat bread, breakfast cereals), fruits and vegetables,
red meat, white meat, fish, nuts and legumes consumption, alcohol intake, and leisure screen time
(i.e., television, video games, computers, etc.). At the final model the variables that were found to be
statistically significant in identifying grade 2 and 3 HTN after the stepwise procedure were legumes
consumption, alcohol intake, sex, age, BMI, and vigorous physical activity, as shown in Table 3.
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Table 3. Scores for European HTN Risk Index.
Hypertension Model b p Value Cut-Offs Points Allocated
BMI
0.001
- <25 kg/m2 0
0.308 25–30 kg/m2 10
0.616 >30 kg/m2 20
Sex
0.001
- female 0
0.204 male 6
Vigorous physical activity
(3 days/ week for at least 10 min)
0.091
- Yes 0
0.048 No 2
Legumes
0.001
- ≥1 cup/week 0
0.254 <1 cup/week 8
Alcohol
(1 portion = 125 mL of wine, 330 mL
of beer or 40mL of hard liquor)
0.020
- <3 portions/week 0
0.069 ≥3 portions/week 2
Age
0.099
- <40 years 0
0.047 ≥40 years 2
Maximum total points 40
b: standardizes-coefficient; BMI: Body Mass Index; HTN: Hypertension.
The ROC analysis in the validation cohort indicated an area under the curve (AUC) 0.768 (95%CI:
0.721–0.815) for identifying individuals above the 75th percentile of HOMA-IR. The index cut-off
score for identifying individuals above the 75th percentile was 23/40, as indicated by the optimal
match of Se and Sp (0.720 and 0.691, respectively) (Table 4, Figure 1). Furthermore, the indicated AUC
for identifying individuals above the 95th percentile of HOMA-IR was 0.828 (95%CI: 0.766–0.890).
The index cut-off score for identifying individuals above the 95th percentile was 31/40, as indicated by
the optimal match of Se and Sp (0.696 and 0.778, respectively) (Table 4, Figure 2). Regarding HTN,
the ROC analysis in the validation cohort indicated an AUC 0.778 (95%CI: 0.680–0.876) for identifying
individuals with grade 2 and 3 hypertension. The index cut-off score for identifying individuals with
grade 2 and 3 hypertension was 26/40, as indicated by the optimal match of Se and Sp (0.667 and 0.797,
respectively) (Table 4, Figure 3).
Table 4. ROC characteristics of European IR Risk Index and European HTN Risk Index in the
validation cohort.
Score AUC 95%
Confidence
Interval
n of TP n of Un PPV % NPV % Se Sp
European IR Risk Index (n = 505)
Cut off score for Identifying individuals
above 75th percentile of HOMA-IR
23/40 0.768 0.721–0.815 95 37 45.5% 87.5% 0.720 0.691
Cut off score for Identifying individuals
above 95th percentile of HOMA-IR
31/40 0.828 0.766–0.890 16 7 13.0% 98.2% 0.696 0.778
European HTN Risk Index (n = 444)
Cut off for detecting 2nd and 3rd
grade hypertension
26/40 0.778 0.680–0.876 14 7 14.0% 97.8% 0.667 0.797
AUC: Area under the ROC Curve, n of TP: Number of true positive, n of un: Number of unidentified, PPV: Positive
predictive value, NPV: Negative predictive value, Se: Sensitivity, Sp: Specificity.
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prevention. Since both of these metabolic abnormalities may be provoked by the interaction of various
risk factors relevant to family history, anthropometric indices and lifestyle parameters, such as dietary
behaviors and physical activity, their assessment is necessary so as to design effective prevention
strategies. Therefore, the development and implementation of screening tools evaluating holistically
various health-related variables can be of a great importance in order to easily identify people at risk,
so as to be referred for further evaluation at primary healthcare settings. The aim of the current study
was to develop two risk assessment indices for the identification of IR and grade 2 and 3 HTN.
A number of risk scores to predict T2DM risk already exist in the literature [14,15,19,31], but most
of them do not apply at various cases such as different races or socioeconomic status. One of
the most reliable and valid tools for the identification of people at increased risk for T2DM is
the FINDRISC [13], which was initially developed on the Finnish population, showing high Se
and Sp values. Thereafter, it has been validated in other European ethnicities with good validity
results [32–35]. Despite the fact that the FINDRISC has been designed on a specific population, it seems
that the use of different cut-offs in different national groups may manage equivalent accuracy [36–38].
Similarly, an accurate easy-to-use online tool for the detection of impaired glucose regulation and
T2DM is the Leicester Risk Assessment Score, an index developed in a multiethnic UK population
with a high probability to identify population at risk [18]. Likewise, the Australian index AUSDRISK
(The Australian Type 2 Diabetes Risk Assessment Tool) is considered of satisfactory Se and Sp but no
studies have examined its validity in different ethnicities [14]. In general, the majority of tools available
in the literature have been found to have satisfactory predictive values, but these values may be limited
in the country developed [31] or some score components that are prerequisite for the completion of some
tools such as blood indices measurements or the awareness of unfavorable glycaemia indices [13,15,19]
makes them non-applicable when individuals have not previously undergone any blood testing.
The aforementioned tools are used for the assessment of the T2DM risk, the early identification
of which is a major public health issue. Indeed, the early identification and management
of IR may significantly decrease the risk for T2DM and cardiovascular disease (CVD) [39].
Furthermore, individuals in the highest HOMA-IR quintiles for IR have even greater risk for CVD [40].
The main benefit of pre-diabetes early identification is that it does not require medical management.
The modification of lifestyle parameters, such as increase physical activity or decrease time devoted to
sedentary activities, weight loss, adopting healthy dietary habits, etc., may be important measures in
order to prevent the onset of glycaemic abnormalities [41–44], and thus to lower its economic public
health burden [45].
Likewise, the existing risk scores for predicting HTN are either developed in population-specific
groups or use as variables the measurements of systolic and diastolic BP [16], which has a large impact
on the feasibility and thus the reach of these screening tools. For instance, the population cohort in
the risk score of Kshirsagar et al. was middle-aged and older adults [17], and despite a satisfactory
AUC (0.75–0.78), it is difficult to apply it in different age groups. Similarly, the risk index of the Strong
Heart Study was developed in an American Indian population [23]. Despite the fact that obesity
and hyperinsulinaemia affect less the BP of American Indians [46], it seems that the development of
HTN in this ethnic group has a more severe effect on cardiovascular health [47]. One of the possible
reasons for these findings in the American Indians is the presence of three genes with multiple single
nucleotide polymorphisms associated with systolic BP [48]. Therefore, the development of more
population-representative and self-reported risk scores is needed to identify HTN accurately.
In the current study, we developed two self-reported risk assessment indices, the European IR
Risk Index and European HTN Risk Index for the identification of IR at 75th and 95th percentile
according to HOMA-IR score and grade 2 and 3HTN. Both risk scores are calculated from a total of
eleven components, and no biochemical, BP or other measurements are required. This makes these
indices very easy-to-calculate, and applicable for a wide range of populations regardless their access
to medical equipment, healthcare services, or their willingness to go through a medical check-up.
Furthermore, by including anthropometric, dietary and physical activity components in the indices,
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the importance of lifestyle modification is highlighted. Specifically, the importance of increasing
physical activity, along with breakfast and legume consumption, and of decreasing sugary drinks and
alcohol consumption is highlighted. In addition, based on the ROC analyses, both the European IR
Risk Index and the European HTN Risk Index were found to perform well in identifying individuals
above 75th and 95th percentile of HOMA-IR and at grade 2 and 3 HTN (Table 4). The AUCs of 0.768,
0.828, 0.778, respectively, are slightly higher than the relevant of risk assessment indices available in the
literature, which range from 0.72 to 0.78 [13,14,17,18,31,49], despite not incorporating biochemical and
BP measurements. Another great advantage of the current indices is that the study population in which
they have been developed and validated is from six countries in Europe, making them applicable and
preferable for a wide range of Caucasian populations. The potential limitations of our study could be
the fact that although it is based on a community cohort, the cohorts recruited from each country are
not representative of the general population, as the recruitment took place only in one large region
within each country, and with probably different risk of developing T2DM than the overall population
according to FINDRISC. Overall, the findings are encouraging for the next steps in validating these
risk assessment indices in more specific European populations.
5. Conclusions
T2DM and HTN are, without any doubt, the major risk factors for CVD. Moreover, there is robust
evidence that they can be prevented and treated through lifestyle interventions. The disparity among
populations around Europe has highlighted the need for simple novel screening tools, without the
use of biochemical or other clinical indices in order to identify individuals at increased risk, so as to
motivate them to seek medical assistance and proceed with lifestyle modification. The developed
European IR Risk Index and European HTN Risk Index in the present study are easy-to-apply, valid,
non-invasive, and low-cost for identifying European adults at high risk for developing T2DM or
having HTN.
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